Clinical trials: Human Papillomavirus-Related Carcinoma
Cervical Cancer, Human Papilloma Virus
HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
Our study will assess and measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections among HPV-vaccinated and 757 HPV-unvaccinated Rwandan WLWH…
- Conditions
- Cervical Cancer, Human Papilloma Virus, Human Immunodeficiency Virus, HPV-Related Carcinoma
- Trial name
- NCT05247853
- Testing
- Blood collection, Oral, cervicovaginal and anal specimen collection, Anoscopy & Biopsy of Acetowhite Lesions
- Where
- Rwanda
- Volunteers
- 3,127 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
HPV-Related Carcinoma
Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls
In 2013, the Investigators enrolled a cohort of 180 HIV-1 infected adolescent girls and boys ages 9-14 years and administered three doses of the QHPV vaccine (NCT04711265).
- Trial name
- NCT04920526
- Testing
- Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine
- Volunteers
- 135 people
- Sponsor
- Kenya Medical Research Institute
Solid Tumor
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers
This is a correlative research project aimed at characterizing the T cell mediated immune responses to hepatocellular carcinoma (HCC), as well as Epstein-Barr virus (EBV)- and human papillomavirus (HPV)-related cancers.
- Trial name
- LANDMARC (NCT04665388)
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- University Health Network, Toronto
Cervical Cancer, HPV-Related Carcinoma
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
- Conditions
- Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma
- Trial name
- NCT06157151
- Testing
- PRGN-2009 plus Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Precigen, Inc
HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited…
- Conditions
- HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma
- Trial name
- NCT06505551
- Testing
- SCG142, Cyclophosphamide, Fludarabine
- Volunteers
- 66 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
Hepatitis B, Human Papilloma Virus
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Aim: The main goal of this quantitative epidemiological observational study is to determine the prevalence of Human Papilloma Virus (HPV) infection and Hepatitis B (Hep B) immunity amongst women of childbearing age.
- Conditions
- Hepatitis B, Human Papilloma Virus, Mental Health Issue, Cancer Liver
- Trial name
- NCT06786429
- Testing
- Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy
- Volunteers
- 2,140 people, healthy volunteers welcome
- Sponsor
- Eunice Dube
Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study
This phase IV trial investigates whether one dose of a human papillomavirus vaccine works as well as two doses in preventing human papillomavirus (HPV) infection. Certain types of HPV cause almost all cases of cervical cancer.
- Trial name
- ESCUDDO (NCT03180034)
- Testing
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Questionnaire Administration, Recombinant Human Papillomavirus Bivalent Vaccine
- Where
- Costa Rica
- Volunteers
- 27,945 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
- Trial name
- NCT06319963
- Testing
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Theravectys S.A.
Head and Neck Cancer, Melanoma
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
The purpose of this study is to obtain archived tumor tissue or pre-existing antigen expression data from patients with Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers to assess antigen expression and patient…
- Conditions
- Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma
- Trial name
- NCT05061940
- Testing
- Tumor Profiling
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Repertoire Immune Medicines
HPV-Related Carcinoma
IBRX-042 In Participants With HPV-Associated Tumors
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV)…
- Trial name
- NCT05976828
- Testing
- IBRX-042
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- ImmunityBio, Inc.
HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand
The purpose of this research is to assess the safety and effectiveness of circumferential radiofrequency ablation (RFA) to the anal canal using the BarrxTM Ablation System to destroy anal high-grade squamous intraepithelial…
- Conditions
- HSIL, High Grade Squamous Intraepithelial Lesions, Anal Cancer, HPV-Related Squamous Cell Carcinoma, Human Papilloma Virus
- Trial name
- NCT03302858
- Testing
- BARRX™ Anorectal Wand
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Stephen E. Goldstone
Oropharynx Cancer, HPV-Related Carcinoma
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3.
- Trial name
- ARTHOUSE (NCT06234748)
- Testing
- Radiation, Platinum based chemotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan Rogel Cancer Center
HPV Infection, HPV-Related Cervical Carcinoma
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
A total of 90 Chinese women aged 9-45 years old were divided into three age groups: 27-45 years old, 18-26 years old, and 9-17 years old. The experimental group and the placebo group were randomly assigned in a ratio of 2:1.
- Trial name
- NCT04083196
- Testing
- 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Human Papillomavirus-Related Cervical Carcinoma
Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort
Human papillomaviruses (HPVs) are the most common of sexually transmitted viral agents and they are associated with genital and oral diseases.
- Trial name
- PAPILLOR (NCT02774538)
- Testing
- Agreement between oral and cervical HPV infection
- Where
- 4 sites in France
- Volunteers
- 165 people
- Sponsor
- Institut de Cancérologie de Lorraine
HPV 16 Infection, HPV-Related Carcinoma
Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection
This healthy related donor clinical trial is linked to a recipient clinical trial protocol for therapeutic purposes. In this healthy donor protocol, haploidentical relatives of a patient with recurrent or metastatic human…
- Conditions
- HPV 16 Infection, HPV-Related Carcinoma, Recurrence, Metastatic Cancer
- Trial name
- J21112LINKED (NCT06508138)
- Testing
- pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Human Papillomavirus-Related Carcinoma
Human Papillomavirus Education Programs
This clinical trial aims to implement a culturally-tailored educational outreach actives with the goal of increasing knowledge of human papillomavirus (HPV) types that can lead to cancer and uptake of the available vaccine.
- Trial name
- NCT04880837
- Testing
- Educational Intervention, Informational Intervention, Survey Administration
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Head Neck Cancer, Oropharyngeal Neoplasms
Human Papillomavirus Association and Genomic Exploration in Head-Neck Squamous Cell Carcinomas
Head and neck squamous cell carcinoma (HNSCC) represents a significant public health burden in Bangladesh with a high incidence and mortality rate.
- Trial name
- HPV & HNSCC (NCT06642324)
- Testing
- Histopathology, Immunohistochemistry, Real-Time PCR, Sequencing
- Where
- Bangladesh
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Oropharyngeal Cancer, Human Papillomavirus-Related Carcinoma
Molecular Signatures of HPV+ ORL Cancers (OROPAP)
The aim of this study is to identify HPV molecular signature in head and neck cancer to establish a new classification for positive human papillomavirus oropharyngeal tumor
- Trial name
- OROPAP (NCT04189003)
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Human Papillomavirus-Related Cervical Carcinoma
Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial
This phase IIIb trial compares a single dose of the Cervarix vaccine in girls to 3 doses of the Gardasil vaccine in young women for the prevention of human papillomavirus (HPV) infection.
- Trial name
- PRIMAVERA (NCT03728881)
- Testing
- Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine, Recombinant Human Papillomavirus Bivalent Vaccine
- Where
- Costa Rica
- Volunteers
- 1,240 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié